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VIRUSES are obligate intracellular parasites which do not normallyremain infective
for long periods outside a living host cell. The associations between viruses and their
hosts may take several forms (Fig. 1). Active replication of virus is followed by lysis
of the infected cells and the duration ofthe illness is usually short. However, in sonme
cases persistent production of virus may be observed over many months or years.
Virus may also become latent in the host tissues and during this time there is no
evidence of viral replication. However under favourable circumstances viral
replication recommences and such 'reactivated' infection may become clinically
apparent. The mechanisms of viral latency are not understood but it is possible that,
as with some oncogenic animal viruses, the viral genome may become incorporated
into the genetic material of the host cell.
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Figure 1. Different ways in which viruses may behave. Note that it is
possible that "latent" viruses may become incorporated into the genome.
During the course of a viral illness specific antibody may limit the spread of the
infection by neutralising extracellular virus whilst thymus derived lymphocytes
(T lymphocytes) destroy virus infected cells. If the cell mediated immune response is
selectively suppressed but humoral antibody responses remain unaffected then
viruses whose mode of spread is to pass between cells in close contact, rather than
via an extracellular route exposed to neutralising antibody, may be expected to
flourish.
THE VULNERABLE HOST
Clinical observation illustrates the practical importance of the different ways in
which viruses are controlled in the normal host. Impaired T-cell function occurs in a
number of congenital thymic dyscrasias, in Hodgkin's Disease and during immuno-
suppressive therapy-for example with azathioprine, anti-lymphocyte globulin and
perhaps with corticosteroids.
In all these instances thereare serious primary and frequent reactivation infections
primarily with herpes group viruses.
22Malnutrition and the metabolic changes of severe uraemia impair T-cell
function, so a patient in renal failure is also vulnerable to viral infections before
transplantation. The indefinite persistence of hepatitis B infection in patients on
regular dialysis exemplifies the impaired immunity of the uraemic host. After
transplantation good renal function may be restored, but immunosuppressive
therapy maintains the hosts vulnerability to virus replication. In some instances the
longterm requirement for immunosuppression provides conditions in which a latent
virus such as Epstein Barr virus (EBV) may induce neoplastic transformation.
It is notable that humoral immune responses are much less severely impaired than
cellular ones by azathioprine or anti-lymphocyte globulin, and so it might be
predicted that infection with viruses readily controlled by circulating antibody
would be less of a problem following renal grafting. This proves to be the case
(Table 1).
TABLE 1
Viruses and Renal Transplantation
Infection Days post-transplant
CMV-primary 21- 90
-reactivation 30-500
HSV -reactivation 10- 90
HVZ primary 10-500
reactivation 50-365
papovavirus reactivation 30-500
The viruses commonly detectedfollowing renal transplantation. It is those viruses
which have thepotential to be latent, or which may bepersistent in the graft itself,
which cause most infections.
VECTORS FOR VIRUS INFECTION
There is little evidence that viral cross-infection is a significant problem in renal
transplant units. This may in part be attributable to awareness by the renal staff of
the hazards of immunosuppressive therapy. It is recognised that close physical
contact is required for the spread of many virus diseases and patients with known
infections are usually isolated and infected staff or visitors excluded from the unit.
Indeed "common" virus infections such as those induced by respiratory or
enteroviruses do not appear to be more common in renal transplant recipients than
in the population as a whole.
It is now clear that the graft itself is an important vector of virus infection.
Cytomegalovirus and papovavirus may be latent in donor renal tissue, probably in
the urothelium while active infection in the donor with hepatitis B virus may be
passively transferred with the graft. There is convincing evidence that renal donors
without clinically apparent CMV infection, but who are seropositive for CMV in the
complement fixation test, carry latent virus and that seronegative recipients become
infected following renal grafting.
23An important question is whether transfusion of stored blood transmits
cytomegalovirus or EB virus. There is convincing evidence that cytomegalovirus is
transferred infresh blood; babies given exchange transfusion or patients subjected
to open heart surgery may become infected as evidenced by seroconversion and
isolation of virus. It is not yet clear if the transfusion of stored blood is a significant
source of virus infection.
SPECIFIC VIRUS INFECTIONS
Cytomegalovirus (CMV)
Evidence of the replication of CMV, as measured by fourfold rise in specific
complement fixation (CF) antibody and/or isolation of the virus, has been found in
up to 95% of renal transplant recipients.I The results of CMV replication may vary
from the asymptomatic infection to fatal disease.2 It is widely accepted that renal
transplant recipients who reactivate their endogenous CMV are usually
asymptomatic whereas patients having a primary infection with this virus following
transplantation have clinically apparent disease (Table 2).
TABLE 2
Cytomegalovirus Induced Illness
Primary infection
(rarely if ever symptomless)
fever
leucopenia
'glandular fever' (Paul-Bunnell negative)
liver cell damage
pneumonia
myocarditis
chorioretinitis
Reactivation N
symptomless seroconversion or virus excretion or
leucopenia and/or fever 90-95
any 'primary' manifestation 5-10
Attempts are being made to protect the seronegative recipient by vaccination with
live attenuated CMV.3 A potential drawback is that the vaccinated subject (when
immunosuppressed) may reactivate the vaccine virus and there is also the theoretical
risk that CMV may be oncogenic. A simple and effective course of action would be
to avoid transplanting kidneys from CMV seropositive donors into seronegative
patients. All transfused blood might also be checked for evidence ofprevious CMV
infection, indicated by the presence of specific antibody, and only seronegative
blood given to seronegative recipients.
24There is no convincing evidence that CMV infection makes graft rejection more
likely or affects the long term survival of the graft. However, it has been suggested4
that a recipient who already carries CMV may transfer it to a grafted kidney derived
from a previously uninfected donor and that impaired renal function may result.
The authors have seen a case in which a graft removed for primary poor function
was heavily infected with CMV although there was no evidence of irreversible
rejection.
Herpes Simplex Virus (HSV)
The emergence of HSV infection following renal transplantation is usually the
result of reactivation of latent virus, often within 30 days of transplant. Sixty to
70%o of renal graft recipients may excrete HSV within the first three months. For
example, Korsager et al,5 in a prospective study, found that 20 of 30 patients
reactivated their latent HSV infections between 23 and 71 days after transplantation.
HSV disease following renal graft is usually confined to the oral or genital regions
(Table 3); rarely disseminated, often fatal, infections are observed. Anuras and
Summers6 describe such a case, with severe hepatitis developing in a 37 year old
male, 3 months after a live donor renal transplant. Recently we have observed
disseminated HSV infection in a 37 year old female renal graft recipient who
excreted HSV in her urine 10 days after transplantation and then followed a rapidly
deteriorating course, with fever, florid stomatitis, vaginal ulceration, herpetic
vesicles on the hands, arms and trunk and evidence of hepatitis. She eventually
succumbed to heart failure caused by ischaemic heart disease 23 days after
transplantation.
TABLE 3
Herpes Simplex Virus (HSV)
HSV-I
847o positive by 40 years.
Lifelong inhabitant.
Latent in cranial ganglia.
Infection:-
Asymptomatic
Mouth
Eye
Finger
Generalised-especially liver
HSV-2
Genital infection.
Latent in sacral ganglia.
Varicella-zoster virus (Herpesvirus varicella HVZ)
Reactivation of latent HVZ expressing itself as herpes zoster, is common after
renal transplantation, although the time of appearance of the lesions may vary
greatly. For example, Rifkind' noted that 6 of 73 (8.2%) renal graft recipients
25developed herpes zoster lesions from 12 to 511 days after transplantation. These
infections usually clear spontaneously.
Epstein Barr virus (EBV)
Excretion of EBV, usually as a result of reactivated infection occurs 3 to 12
months after transplantation.8 The excretion of virus is mainly asymptomatic but
primary infection can be associated with fever and pneumonitis.9 Evidence of EBV
replication has been found in up to 74 per cent of renal transplant recipients.'0
Papovaviruses
Papovavirus infections following renal transplant are usually regarded as
asymptomatic, although Hogan et al II have suggested that the excretion of
papovavirus in urine may be associated with urothelial swelling and obstruction of
the transplanted ureter. Two papovaviruses, designated BK and JC viruses have
been isolated or seen by electron microscopy in the urine of renal transplant
recipients."I 12 These viruses may be reactivated after transplantation as a result of
immunosuppression, as papovaviruses have also been found in patients undergoing
chemotherapy for malignancies.'3
Hepatitis B
Since, in Britain at least, all renal graft recipients, all blood donors and all
potential organ donors are screened for hepatitis B, the risk of its being transmitted
by tissue transfer is very small. There is the interesting possibility that hepatitis B
may, rarely, become latent and develop as a reactivated infection after grafting and
immunosuppression.'4 Analysis of the evidence for this illustrates the difficulty in
differentiating 'latency' from 'persistence'; the latter requires evidence of active
viral replication which may be difficult to obtain with very low grade infections.
Virus infections and oncogenic disease in renalgraft recipients
There are strong associations between some oncogenic conditions and virus
infections particularly in animals. In man the best documented are the associations
between Burkitt's lymphoma, nasopharangeal carcinoma and Epstein Barr virus
(EBV).'5 Less well documented are the relationships between primary liver cell
carcinoma and hepatitis B virus and between CMV and adenocarcinoma of the
colon.'6' 17
Crawford et al'8 and Nagington and Gray'9 have recently drawn attention to a
possible association between EBV and lymphoma, following renal transplantation.
The incidence of lymphoma in renal graft recipients may be higher in patients
immunosuppressed with cyclosporin A than in those in whom conventional
immunosuppression agents are used. Three patients with lymphoma were shown to
have rising antibody to EBV,'9 and a fourth patient had EBV nuclear antigen in cells
of a lymphoma present in his groin.'8 The latter case is the first definitive report
linking EBV with a lymphoma other than Burkitt's lymphoma.
26THERAPY FOR VIRUS INFECTIONS
During the past twenty years, optimism about virus chemotherapy has never
ceased to grow. In particular, a number of drugs can be shown to be effective both
in vitro and in vivo against viruses of the herpes group. Idoxuridine, cytarabine,
vidarabine and more recently acyclovir, all have a place in the management of
herpes simplex virus and varicella-zoster virus disease. Therefore, it is particularly
disappointing that very little, if anything, has been achieved in the case of
cytomegalovirus (CMV). One of the problems appears to be that some of the drugs
are effective in controlling CMV replication but not in clearing the infection. When
therapy is withdrawn, virus excretion rapidly returns to the level existing before
treatment. Idoxuridine and cytarabine are very toxic and prolonged courses
impossible. Vidarabine does not have such serious side effects and is the advocated
drug for the control of zoster in immuno-compromised patients, but there is little
evidence that it achieves very much in the face of CMV. Indeed, recent reports have
suggested that vidarabine is specifically contra-indicated in this group of individuals
because of central nervous system problems.
Acyclovir is a new drug of remarkable promise, because of a highly favourable
therapeutic ratio. Unfortunately, CMV does not code for the kinase which must
phosphorylate acyclovir before it can interfere with the synthesis of virus DNA, and
it does look as though CMV will not be amenable to this drug. In any event, even in
the case of herpes simplex and varicella-zoster, care will be necessary if acyclovir is
used in kidney graft patients, because it can precipitate in the proximal tubules if
renal function is inadequate.
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